349 related articles for article (PubMed ID: 27941285)
1. [Basics of cancer immunotherapy].
Fujioka Y; Nishikawa H
Rinsho Ketsueki; 2016; 57(11):2346-2354. PubMed ID: 27941285
[TBL] [Abstract][Full Text] [Related]
2. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
3. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
4. Tim-3 and its role in regulating anti-tumor immunity.
Das M; Zhu C; Kuchroo VK
Immunol Rev; 2017 Mar; 276(1):97-111. PubMed ID: 28258697
[TBL] [Abstract][Full Text] [Related]
5. Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.
Hegde UP; Mukherji B
Cancer Immunol Immunother; 2017 Sep; 66(9):1113-1121. PubMed ID: 28497159
[TBL] [Abstract][Full Text] [Related]
6. [Cancer immunotherapy by immuno-checkpoint blockade].
Kawakami Y
Rinsho Ketsueki; 2015 Oct; 56(10):2186-94. PubMed ID: 26458459
[TBL] [Abstract][Full Text] [Related]
7. [Recent advances and future challenges in cancer immunotherapy].
Okuyama N; Tamada K; Tamura H
Rinsho Ketsueki; 2016; 57(11):2388-2395. PubMed ID: 27941290
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cells in cancer immunotherapy.
Nishikawa H; Sakaguchi S
Curr Opin Immunol; 2014 Apr; 27():1-7. PubMed ID: 24413387
[TBL] [Abstract][Full Text] [Related]
9. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
10. [Suppression of tumor antigen-specific T cell immune responses by regulatory T cells].
Shimazu Y; Nishikawa H
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1057-61. PubMed ID: 25248887
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
Weber J
Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
[TBL] [Abstract][Full Text] [Related]
12. Emerging targets in cancer immunotherapy.
Burugu S; Dancsok AR; Nielsen TO
Semin Cancer Biol; 2018 Oct; 52(Pt 2):39-52. PubMed ID: 28987965
[TBL] [Abstract][Full Text] [Related]
13. The Breakthroughs in Cancer Immune Checkpoint Based Therapy: A Review of Development in Immune Checkpoint Study and its Application.
Huang Y; Liang D; Liu J; Zeng J; Zeng Y
Comb Chem High Throughput Screen; 2017; 20(5):430-439. PubMed ID: 28302019
[TBL] [Abstract][Full Text] [Related]
14. The nephrotoxicity of new immunotherapies.
Sury K; Perazella MA
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):513-521. PubMed ID: 31035801
[No Abstract] [Full Text] [Related]
15. Immunotherapy of cancer: from vision to standard clinical practice.
Huber CH; Wölfel T
J Cancer Res Clin Oncol; 2004 Jul; 130(7):367-74. PubMed ID: 15067541
[TBL] [Abstract][Full Text] [Related]
16. Immune targets and neoantigens for cancer immunotherapy and precision medicine.
Wang RF; Wang HY
Cell Res; 2017 Jan; 27(1):11-37. PubMed ID: 28025978
[TBL] [Abstract][Full Text] [Related]
17. [Era of cancer immunotherapy has come].
Nakatsura T
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):164-71. PubMed ID: 27320931
[TBL] [Abstract][Full Text] [Related]
18. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
Music M; Prassas I; Diamandis EP
Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
[TBL] [Abstract][Full Text] [Related]
19. Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.
Lohmueller J; Finn OJ
Pharmacol Ther; 2017 Oct; 178():31-47. PubMed ID: 28322974
[TBL] [Abstract][Full Text] [Related]
20. [Development of novel immunotherapy targeting cancer immune evasion].
Tamada K
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1062-5. PubMed ID: 25248888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
